GlassScriptPhysician profile
Jose A Silva
NPI 1790765394
$10,494.74
in general payments reported to CMS, 2019-2025
24 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $88.39 · 2021: $180 · 2022: $109 · 2023: $6,039 · 2024: $3,424 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $8,389 · Food and Beverage: $1,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $8,389.34 |
| Food and Beverage | $1,288.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $8,965.64 | 2023-2025 | Auryon Laser System 100-120 Vac, Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| Baylis Medical Company INC | $352.30 | 2019 | |
| Boston Scientific Corporation | $308.06 | 2019-2025 | Peripheral Rotalink Plus, Bodyguardian, Rotapro |
| Abbott Laboratories | $174.92 | 2023-2025 | Diamondback Peripheral, Perclose Proglide, Esprit |
| Medtronic Vascular, INC. | $75.99 | 2019-2020 | |
| Veryan Medical Incorporated | $68.79 | 2021-2022 | |
| Amgen INC. | $65.19 | 2024-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $59.43 | 2021-2024 | |
| Cardiva Medical, INC. | $59.03 | 2023-2024 | Cardiva Vascade 6/7f Vcs |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.77 | 2019-2022 | |
| Abiomed | $46.97 | 2021 | |
| Bard Peripheral Vascular, INC. | $42.15 | 2022-2025 | Venclose Maven Catheter |
| Becton, Dickinson and Company | $32.66 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $28.72 | 2025 | Exparel, Iovera |
| Venclose INC. | $22.05 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $19.32 | 2024 | Brite Tip Radianz |
| Smith+Nephew, INC. | $18.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.52 | 2022 | |
| Cardiovascular Systems INC. | $16.42 | 2023 | Diamondback Coronary |
| Bayer Healthcare Pharmaceuticals INC. | $15.37 | 2021 | |
| Tactile Systems Technology INC | $15.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.62 | 2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $13.48 | 2023 | Xarelto |
| Flowphysix INC | $8.35 | 2025 | Flowrunner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.